HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The Effects of Human Milk Oligosaccharides on Gut Microbiota, Metabolite Profiles and Host Mucosal Response in Patients with Irritable Bowel Syndrome.

AbstractBACKGROUND:
Human milk oligosaccharide supplementation safely modulates fecal bifidobacteria abundance and holds the potential to manage symptoms in irritable bowel syndrome (IBS). Here, we aimed to determine the role of a 4:1 mix of 2'-O-fucosyllactose and lacto-N-neotetraose (2'FL/LNnT) on the modulation of the gut microbiota composition and host mucosal response, as well as the link between the bifidobacteria abundance and metabolite modulation, in IBS patients.
METHODS:
Biological samples were collected from IBS patients (n = 58) at baseline and week 4 post-supplementation with placebo, 5 g or 10 g doses of 2'FL/LNnT. The gut microbiota composition, metabolite profiles and expression of genes related to host mucosal response were determined.
RESULTS:
Moderate changes in fecal, but not mucosal, microbial composition (β-diversity) was observed during the intervention with higher dissimilarity observed within individuals receiving 10g 2'FL/LNnT compared to placebo. Both fecal and mucosal Bifidobacterium spp. increased after 2'FL/LNnT intake, with increased proportions of Bifidobacterium adolescentis and Bifidobacterium longum. Moreover, the intervention modulated the fecal and plasma metabolite profiles, but not the urine metabolite profile or the host mucosal response. Changes in the metabolite profiles were associated to changes in bifidobacteria abundance.
CONCLUSION:
Supplementation with 2'FL/LNnT modulated the gut microbiota, fecal and plasma metabolite profiles, but not the host mucosal response in IBS. Furthermore, the bifidogenic effect was associated with metabolite modulation. Overall, these findings support the assertion that 2'FL/LNnT supplementation modulate the intestinal microenvironment of patients with IBS, potentially related to health.
AuthorsCristina Iribarren, Maria K Magnusson, Louise K Vigsnæs, Imran Aziz, Ingvild Dybdrodt Amundsen, Tanja Šuligoj, Nathalie Juge, Piyush Patel, Maria Sapnara, Lea Johnsen, Nikolaj Sørensen, Johanna Sundin, Hans Törnblom, Magnus Simrén, Lena Öhman
JournalNutrients (Nutrients) Vol. 13 Issue 11 (Oct 27 2021) ISSN: 2072-6643 [Electronic] Switzerland
PMID34836092 (Publication Type: Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial)
Chemical References
  • Oligosaccharides
  • Trisaccharides
  • lacto-N-neotetraose
  • 2'-fucosyllactose
Topics
  • Adolescent
  • Adult
  • Aged
  • Bifidobacterium (drug effects)
  • Dietary Supplements
  • Double-Blind Method
  • Feces (microbiology)
  • Female
  • Gastrointestinal Microbiome (drug effects)
  • Humans
  • Intestinal Mucosa (drug effects)
  • Irritable Bowel Syndrome (drug therapy, microbiology)
  • Male
  • Middle Aged
  • Milk, Human (chemistry)
  • Oligosaccharides (pharmacology)
  • Treatment Outcome
  • Trisaccharides (pharmacology)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: